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Movement disorders include both psychiatric illnesses with neurologic features and 
neurologic illnesses with frequent psychiatric complications. During 1998, neuropsychiatric 
progress was made on several fronts, notably in parkinsonism and tic disorders. This remains an 
exciting area for research, with many unsolved, clinically important problems, but increasing 
neurobiologic knowledge and sophistication. 
 
Introduction 
The term “movement disorders” is applied to a large and heterogeneous group of illnesses 
that affect the quality of volitional movement, produce unwanted excessive movements, or both. 
Phenomenologically, the abnormal movements include the parkinsonian syndrome, tremor, 
dystonia, chorea, myoclonus, hyperekplexia, and stereotypies. Many of these illnesses are often 
accompanied by disturbances of perception, memory, language, or mood. Additionally, several 
movement abnormalities have interested psychiatrists of their own right, including tic disorders, 
catatonia, the motor retardation of melancholic depression, odd movements as a feature of 
hysteria, and tardive movement disorders. During the past year, exciting new results have been 
reported in several of these areas. 
 
Neuropsychiatry of parkinsonism 
Cognition in parkinsonian disorders 
A variety of cognitive deficits have been described in PD.  The most well characterized 
are relatively subtle deficits that are usually attributed to dysfunction of frontal corticostriatal 
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circuits [1].  These include difficulties with shifting, sequencing, or maintaining behavioral set in 
the face of interfering stimuli.  It has not been clear if the “frontal” dysfunction in PD is due to 
loss of dopamine innervation of frontal cortex, or to loss of the normal basal ganglia output to 
frontal cortex (via thalamus), or to a combination [2].  A recent study comparing patients with 
early PD to patients with damage to the left or right frontal lobes demonstrated clear differences 
between the groups [*3]. PD subjects showed an increased error rate as they performed 
successive trials, but not an increased time to switch between tasks.  The authors suggested that 
intact dopamine neurotransmission is required to sustain cognitive and motor processes over 
prolonged time periods. 
Another relatively common cognitive difficulty in PD is the development of dementia.  It 
has been estimated that 10 - 20 % of patients with PD eventually become severely demented [4].  
It is becoming increasingly clear, however, that dementia in PD is not due primarily to 
nigrostriatal dopamine loss, but is due instead to other mechanisms including coexistent 
Alzheimer’s disease, multi-system atrophy with loss of other subcortical nuclei, or diffuse Lewy 
body disease (DLBD) [5,6].  Churchyard and Lees [**7] examined the brains of 27 patients 
diagnosed during life with PD and compared them with 11 control brains.  None of the subjects 
met clinical diagnostic criteria for DLBD, the Lewy body variant of Alzheimer's disease, or 
senile dementia of the Lewy body type.   Five PD patients, 2 with moderate dementia and 3 with 
severe dementia, met pathological criteria for DLBD.  There was no difference between PD 
brains and controls in measures of neuronal density, neurofibrillary tangles, or neuritic plaques in 
the hippocampus or amygdala.   There was an increased density of Lewy bodies in hippocampal 
region CA2 in severely demented PD brains, but no correlation with severity of dementia.  
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However, increasing Lewy neurite densities in CA2 was related to worsening dementia as 
assessed by the mini-mental status exam and DSM-III criteria.  The authors suggested that 
Parkinson’s disease and dementia with Lewy bodies overlap both clinically and pathologically. 
Another recent study used MRI volumetric analysis to investigate the relationship 
between hippocampal size and deficits on verbal, visual, or spatial memory or set-shifting ability 
in non-demented PD subjects [8].  The authors found an inverse relationship between 
performance on visual or verbal memory tasks and hippocampal volume.  There was no 
relationship between performance on spatial working memory or set-shifting tasks and 
hippocampal volume.  They concluded that memory deficits in PD are due to hippocampal 
atrophy.   These results appear to differ with those of Churchyard and Lees [**7] who reported 
no hippocampal atrophy in demented PD subjects.  However, the volume loss as seen with MRI 
may not be due to change in neuronal density. 
 
Mood disorders in PD 
One important complication of PD and its treatment is the development of mood 
fluctuations which parallel plasma levodopa levels. Maricle and colleagues have reported several 
studies of this phenomenon, confirming that this is most likely a direct cerebral effect of 
levodopa [9,10]. They have now shown that earlier in PD, patients show smaller fluctuations in 
mood [**11]. This fits well with the hypothesis that mood fluctuations in advanced PD are 
similar in etiology (though probably different in functional neuroanatomy) to motor fluctuations. 
A large minority of PD patients have persistent major depression. Unfortunately, there is 
little sound data on treatment; one review found no published study with adequate methodology 
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[12]. Recent reports include a survey of neurologists from the Parkinson’s Study Group 
regarding antidepressant treatment [*13], and a study in which moclobemide was added to 
selegiline for treatment of depression in PD [*14]. A retrospective study of ECT for depression in 
PD [*15] confirmed that ECT is an effective antidepressant treatment in PD patients, though 
delirium was a frequent and serious side effect [16]. 
 
Psychosis in PD 
Psychosis is a frequent complication of PD and probably a substantial risk for nursing 
home placement and death [17,18]. However, 46 years after chlorpromazine, there is still no 
peer-reviewed, methodologically adequate trial of any antipsychotic in this population. Perhaps 
the best published study was the 1996 report on olazapine, but in that study raters were aware of 
treatment assignment [19]. Fortunately, we will not have to wait much longer. A presentation at 
the 1998 American Academy of Neurology meeting described a multicenter, double-blind, 
placebo-controlled study of clozapine in PD [**20]. Also, several small case series suggested 
that initial enthusiasm about risperidone, olanzapine and quetiapine must be tempered by the fact 
that they can occasionally cause significant worsening of parkinsonism in this population 
[21,22,*23,24,25,26,27,28]. More rigorous data are required before we can decide the merits of 
any of the newer antipsychotics in PD. 
The neurobiology of psychosis in PD is still largely unknown, but a pilot study by Goetz 
and colleagues [*29] confirms clinical evidence that levodopa-induced hallucinations are a long-
term rather than immediate effect of levodopa. Two recent phenomenological studies [*30,*31] 
show that PD patients who develop psychosis early in their course may comprise a different 
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group than patients who develop psychosis only in late PD, often accompanied by dementia or 
depression. However, the suggestion [*29] that psychosis early in the course of parkinsonism 
requires a diagnosis other than idiopathic PD seems premature, pending (1) studies in which 
parkinsonian etiology is ascertained blind to presence of psychosis, and (2) firmer consensus on 
the nosology of diffuse Lewy body disease and parkinsonism with Alzheimer’s disease. Auditory 
hallucinations are less common than visual hallucinations but clearly occur in PD patients [32]. 
 
Huntington’s Disease 
One simple but clever study attempted to “determine why patients with Huntington 
disease (HD) are apparently unaware of their involuntary movements” [*33]. The results support 
the view that patients have a form of anosognosia rather than dementia or psychologically 
motivated denial. 
Two reports address the question of whether cognitive deficits can be identified in 
asymptomatic gene carriers for HD. Clinically unaffected carriers showed no significant 
cognitive deficits in one study [*34]. In a larger study [**35], logical and verbal memory test 
performance was worse in neurologically normal at-risk individuals who later were found to 
have abnormal versus normal number of CAG repeats in the huntingtin gene. Additionally, gene 
carriers with higher repeat numbers tended to do worse on several tests. These studies show that 
there are statistically significant, but clinically subtle, cognitive disturbances before development 
of abnormal neurological signs in HD. However, motor abnormalities below the neurological 
exam threshold may precede these cognitive abnormalities. 
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Psychological symptoms in dystonia 
An interview study of 44 adult patients with cervical dystonia found frequent panic 
disorder, major depression, and OCD [*36]. The 66% frequency of diagnosable psychiatric 
illness in this group implies that, contrary to suggestions in the literature [37], the presence of 
preexisting mental illness is unreliable as an indicator of atypical or “psychogenic” dystonia. 
 
Pathophysiology of Tics 
The prevailing hypothesis of tic pathophysiology involves increased dopamine activity in 
basal ganglia circuits.  This idea is variably supported by neurochemical, functional imaging, and 
clinical pharamacologic data [38].  Recent support comes from functional MRI findings of 
BOLD signal changes in basal ganglia and thalamus that correlated inversely with tic severity 
during attempts to suppress the tics [39].  One prediction of this hypothesis is that dopamine 
depletion should decrease or eliminate tics.  However, a recent report of 4 individuals with tics 
beginning in childhood and Parkinson’s disease beginning in later adulthood found that tics 
neither decreased with onset of PD nor worsened with dopamimetic treatment [*40]. This 
suggests that tics are not exclusively due to functional overactivity of the dopamine system, but 
must involve other systems as well. 
Over the past several years, there has been increasing evidence for a post-infectious or 
immune-mediated mechanism in some individuals with tics or TS. It has long been known that 
neurologic illness, especially Sydenham (rheumatic) chorea, can follow group A beta-hemolytic 
streptococcal (GABHS)  infections [41]. Less well-known is that obsessions, compulsions, 
inattentiveness, tics, and even mania can accompany Sydenham chorea [41,42]. Thus, it may not 
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be surprising that some individuals develop obsessive-compulsive disorder (OCD), tics 
(including Tourette syndrome), or both in close temporal relationship to an antecedent GABHS 
infection. Post-infectious onset of tics or OCD has been an area of active research by several 
investigators [**43]. Although tics associated with infections other than strep have been reported, 
including Lyme disease [44], the strep association appears to be the most convincing. A group at 
the NIMH has coined the term PANDAS (Pediatric Autoimmune Neuropsychiatric Disorder 
Associated with Streptococcal infection) and has recently published a description of their first 50 
patients [*45]. They define PANDAS by abrupt childhood onset of OCD or tics, temporally 
related to GABHS infection, with neurologic signs (hyperactivity, choreiform movements, tics) 
during an exacerbation. 
Support for PANDAS as a possible etiology of tics comes from several independent lines 
of evidence, as reviewed recently by Kurlan [**43].  Two lines of evidence will be discussed 
here.  One is the presence of antineuronal antibodies in subjects with TS.  Singer et al. [**46] 
found increased levels of antibodies against putamen in 41 children with TS compared to 39 age-
matched controls.  However, there was substantial overlap. In TS subjects, these antibodies were 
more common in those with serologic evidence of GABHS infection. There was no association 
between elevated antineuronal antibodies and age of tic onset, tic severity, sudden onset of tics, 
presence of OCD, or presence of ADHD. 
The second line of evidence concerns the presence of markers associated with acute 
rheumatic fever in individuals without rheumatic fever, but with tics or OCD.  One such marker 
is a B cell surface marker called D8/17.  This marker had is present in 90 - 100% of subjects with 
rheumatic fever and virtually absent in controls [47].  In a study by Murphy et al. [48], patients 
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with either TS or OCD, but without rheumatic fever, had an elevated average percentage of B 
cells expressing D8/17.  All patients but only one control were considered D8/17 positive.  
Another study investigated the frequency of D8/17 positive individuals among groups of 27 
children with PANDAS, 9 children with Sydenham chorea, and 24 healthy controls [49].  They 
found that 85% of the PANDAS group, 89% of the Sydenham chorea group, and 17% of the 
control group were D8/17 positive.  Thus, some individuals with tics or OCD appear to share a 
genetic marker with individuals who are susceptible to developing rheumatic fever.  This lends 
support to the notion that in some predisposed individuals, tics or OCD may be a manifestation 
of post-streptococcal immune-mediated disease. 
Although many studies have suggested an autosomal dominant inheritance of TS, 
attempts to identify a specific gene have been unsuccessful, as reviewed recently [*50].  One 
approach has been to test candidate genes in neurotransmitter systems thought to be involved in 
TS.  Previous studies have suggested that the dopamine receptor D2, D3, or D4 loci might be 
implicated in TS, but other studies have not confirmed those findings [*50].  A recent report 
using single stranded conformational polymorphism analysis of the D1 receptor gene failed to 
demonstrate any mutations in subjects with TS [51]. 
 
Comorbidity in Tourette Syndrome 
Although TS is defined solely by tics, many TS patients find other symptoms more 
problematic, especially obsessions, compulsions, or impaired attention or learning. An important 
unanswered question is whether comorbid psychological symptoms define a clinically 
meaningful subgroup of TS. 
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In a multicenter German family study of TS and OCD, obsessions and compulsions (OC 
symptoms) were more frequent in relatives of TS patients who themselves had OC symptoms 
[**52]. However, OC symptoms in relatives were most likely caused by the same gene(s) as tics, 
as they were usually accompanied by tics (in male relatives). Also, if OC symptoms were present, 
their severity, including the diagnostic threshold for OCD, was irrelevant to heritability of either 
tics or OC symptoms. These findings support the concept that the presence or absence of OC 
symptoms may be a biologically meaningful clinical feature of TS. This study also reports 
several other clinically relevant findings, including the observation that five relatives had 
otherwise typical tic syndromes but definitely dated tic onset to after age 21. 
Another report also supports the validity of subdividing TS by presence or absence of OC 
symptoms. A group from Harvard [**53] examined 61 patients with TS, OCD, or both (TS-OCD) 
for various other psychiatric syndromes. The rates for most mood and anxiety disorders did not 
differ between the TS-only group and the OCD-only group. However, the 3 groups differed 
significantly in rates of bipolar disorder, social phobia, body dysmorphic disorder (BDD), 
trichotillomania, attention deficit hyperactivity disorder (ADHD), and substance abuse. To 
summarize, the TS+OCD group had the highest frequency of comorbidity, ADHD segregated 
with tics, and (surprisingly) BDD also seemed more closely related to TS. The authors conclude 
that TS+OCD has more substantial comorbidity than either diagnosis alone, and that this group is 
probably linked more closely to TS than to OCD. 
In this study, three of 20 patients with both TS and OCD met criteria for bipolar disorder 
[**53]. Given a population prevalence for bipolar disorder of <1%, the 15% prevalence here is 
remarkable. However, a study from Spain found that 12% of 90 consecutively examined patients 
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with TS had either bipolar disorder or schizoaffective disorder, and an additional 21% had 
bipolar II disorder or cyclothymia [54]. The majority of these patients (80%) also had OCD, and 
many of them reported fewer tics during depressive episodes and more with manic episodes [54]. 
This surprising prevalence of manic illness in TS+OCD patients is probably not due to excessive 
symptom reporting in general, as this group reported less panic disorder or agoraphobia than the 
other groups [**53]. Further studies of this difficult to treat subgroup are warranted. 
 
Tardive movement disorders 
Molho et al [**55] contrasted clinical features of torticollis patients with presumed 
tardive or primary etiologies. Contrary to clinical lore, several clinically useful distinctions were 
found. Another large report on tardive cervical dystonia also found frequent retrocollis [*56]; 
although the disease was chronic, stopping neuroleptics could clearly help the dystonia. 
A large prospective study on the incidence of tardive dyskinesia (TD) in the elderly found 
staggeringly high cumulative rates of 25% and 53% after 1 and 3 years of total antipsychotic 
treatment, respectively [**57]. Surprisingly, a past history of electroconvulsive therapy treatment 
was a strong risk factor for later development of TD; whether this reflects diagnosis, severity of 
illness, or other symptomatic features remains to be shown. A meta-analysis of vitamin E 
treatment of TD concludes that a subgroup of patients shows statistically meaningful but 
clinically modest benefit without substantial side effect risk [58]. However, methodological 
flaws in several of the studies reviewed render these conclusions tentative. In a randomized study, 
fully informed consent regarding TD risk did not negatively affect antipsychotic compliance [59]. 
The availability of a direct genetic test for HD allowed a study of 12 patients with 
This is a non-final version of an article published in final form in: Black KJ, Mink JW. 




presumed senile chorea to conclude that six had Huntington’s disease with a negative family 
history [60]; this has implications for prior studies of “spontaneous” dyskinesias in the elderly. 
On the other hand, the existence of abnormal movements in never-treated subjects with 
schizotypal personality disorder [61] or schizophrenia suggests that movement disorder may be 
an integral part of these illnesses [62]. However, in this study and in prior reports on untreated 
schizophrenia, the abnormal movements observed are often complex and are generally not the 
orofacial stereotypies with tongue protrusion which are typical of tardive dyskinesia. 
 
Catatonia and neuroleptic malignant syndrome 
Two interesting reports on the genetics of periodic catatonia, an illness marked by 
relapsing and remitting catatonic episodes, involved 83 probands [63,64]. The authors found 
evidence for a single major gene effect with genetic anticipation and a 27% risk to first-degree 
relatives. There was a trend (p < 0.10) for paternal transmission of illness to be associated with 
younger age of onset in the probands. These results are preliminary but may be consistent with a 
triple repeat mechanism. 
A case-control of study neuroleptic malignant syndrome (NMS) confirmed previously 
reported risk factors for development of NMS, including parenteral administration of 
neuroleptics and catatonia, and also revealed risks for agitation, parkinsonism, akathisia, and 
neuroleptic dosing [*65]. Another study [66] examined the relationship between catatonia, NMS, 
and low serum iron, an acute phase reactant which had previously been found in NMS [67]. Low 
serum iron was found in every instance of “malignant catatonia” (NMS-like without neuroleptic 
exposure), and these patients had a high risk of NMS upon exposure to neuroleptics. Some 
This is a non-final version of an article published in final form in: Black KJ, Mink JW. 




catatonic patients without malignant features also had low serum iron, but these patients did not 
tend to develop NMS. These interesting results may indicate a clinically meaningful subdivision 
of catatonia, and deserve confirmation in prospective studies. 
 
Conclusion 
Important advances were reported in 1998 in the neuropsychiatry of movement disorders. 
We should soon see the long-awaited publication of adequate treatment studies of psychosis in 
Parkinson’s disease. Also, increasing evidence supports the hypothesis that some cases of 
Tourette syndrome or OCD may be caused by autoimmune responses to streptococcal infections. 
However, at our current stage of knowledge, it remains appropriate to study TS using several 
different approaches, including genetic and neuroimaging studies. Exciting research opportunites 




 1.  Brown RG, Marsden CD. Cognitive function in Parkinson's disease: from 
description to theory. TINS 1990; 13:21-29. 
 2.  Mink JW. The basal ganglia: Focused selection and inhibition of 
competing motor programs. Progress in Neurobiology 1996; 50:381-425. 
 3.  Rogers RD, Sahakian BJ, Hodges JR, Polkey CE, Kennard C, Robbins TW. 
Dissociating executive mechanisms of task control following frontal lobe damage 
and Parkinson's disease. Brain 1998; 121:815-842. 
* This is a report of different deficits among patients with frontal lobe lesions or 
Parkinson's disease in a task-switching paradigm.  The Parkinson's disease patients 
showed an increase in error rate as they performed succesive trials, but not an 
increased time to switch between tasks.  The authors suggest that intact dopamine 
neurotransmission is required to sustain cognitive and motor processes over 
prolonged time periods. 
This is a non-final version of an article published in final form in: Black KJ, Mink JW. 




 4.  Brown RG, Marsden CD. How common is dementia in Parkinson's 
disease? Lancet 1984; 2:1262-1265. 
 5.  Gordon MF, Weiner WJ, Koller WC, Rao TH, Chehebar V, Dickson DW. 
What is it? Case 2, 1994: Parkinsonism and cognitive impairment. Mov Disord 
1994; 9:679-686. 
 6.  Watts, RL, Koller, WC. Movement Disorders - Neurologic Principles and 
Practice. New York: McGraw-Hill, 1997:779 
 7.  Churchyard A, Lees A. The relationship between dementia and direct 
involvement of the hippocampus and amygdala in Parkinson's disease. Neurology 
1997; 49:1570-1576. 
** The authors examined the brains of 27 patients who had been diagnosed with 
Parkinson's disease during life.  The severity of cognitive impairment was 
correlated with the density of Lewy neurites in region CA2 of the hippocampus. The 
authors suggest that Parkinson's disease with dementia and dementia with Lewy 
bodies are overlapping clinical and pathological entities. 
 8.  Riekkinen Jr. P, Kejonen K, Laakso M, Soininen H, Partanen K, Riekkinen 
M. Hippocampal atrophy is related to impaired memory, but not frontal functions in 
non-demented Parkinson's disease patients. Neuroreport 1998; 9:1507-1511. 
 9.  Maricle RA, Nutt JG, Valentine RJ, Carter JH. Dose-response relationship 
of levodopa with mood and anxiety in fluctuating Parkinson's disease: a double-
blind, placebo-controlled study. Neurology 1995; 45:1757-1760. 
 10.  Maricle RA, Nutt JG, Carter JH. Mood and anxiety fluctuation in 
Parkinson's disease associated with levodopa infusion: preliminary findings. Mov 
Disord 1995; 10:329-332. 
 11.  Maricle RA, Valentine RJ, Carter J, Nutt JG. Mood response to levodopa 
infusion in early Parkinson's disease. Neurology 1998; 50:1890-1892. 
** This is a carefully executed study of levodopa-induced mood fluctuations in 
Parkinson's disease which extends the authors' earlier work to patients with milder 
disease and shorter treatment histories. 
 12.  Klaassen T, Verhey FR, Sneijders GH, Rozendaal N, de Vet HC, van Praag 
HM. Treatment of depression in Parkinson's disease: a meta-analysis. J 
This is a non-final version of an article published in final form in: Black KJ, Mink JW. 




Neuropsychiatry Clin Neurosci 1995; 7:281-286. 
 13.  Richard IH, Kurlan R, Parkinson Study Group. A survey of antidepressant 
drug use in Parkinson's disease. Neurology 1997; 49:1168-1170. 
* A survey of neurologists from the Parkinson's Study Group found that a quarter of 
their patients were being treated with an antidepressant, but of these almost half 
were taking tricyclic agents. As dose was not specified and many respondents 
reported they chose tricyclics in part for their hypnotic effects, the adequacy of 
treatment in many depressed PD patients is suspect. 
 14.  Jansen Steur ENH, Ballering LAP. Moclobemide and selegeline in the 
treatment of depression in Parkinson's disease. J Neurol Neurosurg Psychiatry 1997; 
63:547-547. 
* Selegiline (an MAO-B inhibitor at the doses used) was found to confer additional 
benefit when added to moclobemide (a reversible MAO-A inhibitor) in treating 
depressed patients with PD. However, these results will need confirmation in a 
blinded, randomized allocation study, and comparison to the simpler strategy of 
using a nonselective MAO inhibitor or a higher dose of selegiline, before this 
treatment option has clear utility. 
 15.  Moellentine C, Rummans T, Ahlskog JE, Harmsen WS, Suman VJ, 
O'Connor MK, et al. Effectiveness of ECT in patients with parkinsonism. J 
Neuropsychiatry Clin Neurosci 1998; 10:187-193. 
* Twenty-five depressed PD patients treated with electroconvulsive therapy (ECT) 
were compared retrospectively to 25 non-PD ECT patients matched for age and 
gender. ECT was clearly effective as an antidepressant, but nearly half their 
patients developed confusion on days between treatments. 
 16.  Figiel GS, Hassen MA, Zorumski CF, Krishnan KRR, Doraiswamy PM, 
Jarvis MR, et al. ECT-induced delirium in depressed patients with Parkinson's 
disease. J Neuropsychiatry Clin Neurosci 1991; 3:405-411. 
 17.  Goetz CG, Stebbins GT. Mortality and hallucinations in nursing home 
patients with advanced Parkinson's disease. Neurology 1995; 45:669-671. 
 18.  Goetz CG, Stebbins GT. Risk factors for nursing home placement in 
advanced Parkinson's disease. Neurology 1993; 43:2227-2229. 
 19.  Wolters EC, Jansen ENH, Tuynman-Qua HG, Bergmans PL. Olanzapine 
in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. 
This is a non-final version of an article published in final form in: Black KJ, Mink JW. 




Neurology 1996; 47:1085-1087. 
 20.  Friedman JH, Lannon MC, Factor SA, Comella C, Parsa M, Pfeiffer R, et 
al. Low dose clozapine for the treatment of drug-induced psychosis (DIP) in 
idiopathic Parkinson's disease (PD): results of the double-blind, placebo-controlled 
PSYCLOPS trial. Neurology 1998; 50:A70-A70. 
** This is only an abstract, but represents the first successful, methodologically 
adequate study of this clinically very important illness. Low-dose clozapine 
successfully treated positive symptoms without worsening of parkinsonism. One of 
60 patients experienced transient leukopenia. 
 21.  Friedman JH, Goldstein S, Jacques C. Substituting clozapine for 
olanzapine in psychiatrically stable Parkinson's disease patients: results of an open 
label pilot study. Clinical Neuropharmacology 1998; 21:285-288. 
 22.  Jiménez-Jiménez FJ, Tallón-Barranco A, Ortí-Pareja M, Zurdo M, Porta J, 
Molina JA. Olanzapine can worsen parkinsonism. Neurology 1998; 50:1183-1184. 
 23.  Friedman JH. Olanzapine in the treatment of dopaminomimetic psychosis 
in patients with Parkinson's disease. Neurology 1998; 50:1195-1196. 
* The author describes his clinical experience with olanzapine in several 
parkinsonian patients with psychosis. The majority had improvement of psychosis, 
but several patients developed delirium or clinically significant worsening of 
parkinsonian motor signs. The reply from Wolters et al reminds us that the 
methodologically best published study found no significant motor deterioration with 
olanzapine, and suggests that in their experience, younger, nondemented PD 
patients without agonist treatment may do better with olanzapine. 
 24.  Rosenfeld MJ, Friedman JH, Jacques C. Quetiapine pilot trial in 
dopamimetic psychosis (DP) in Parkinson's disease (PD). Mov Disord 1998; 
13:242-242. 
 25.  Samanta J, Stacy M. Quetiapine in the treatment of hallucinations in 
advanced Parkinson's disease. Mov Disord 1998; 13:274-274. 
 26.  Friedman JH, Ott BR. Should risperidone be used in Parkinson's disease? 
J Neuropsychiatry Clin Neurosci 1998; 10:473-475. 
 27.  Parsa MA, Bastani B. Quetiapine (Seroquel) in the treatment of psychosis 
This is a non-final version of an article published in final form in: Black KJ, Mink JW. 




in patients with 
Parkinson's disease. J Neuropsychiatry Clin Neurosci 1998; 10:216-219. 
 28.  Graham JM, Sussman JD, Ford KS, Sagar HJ. Olanzapine in the treatment 
of hallucinosis in idiopathic Parkinson's disease: a cautionary note. J Neurol 
Neurosurg Psychiatry 1998; 65:774-777. 
 29.  Goetz CG, Pappert EJ, Blasucci LM, Stebbins GT, Ling ZD, Nora MV, et 
al. Intravenous levodopa in hallucinating Parkinson's disease patients: high-dose 
challenge does not precipitate hallucinations. Neurology 1998; 50:515-517. 
* Five PD patients with hallucinations during the ordinary course of treatment 
received 1.5mg/kg levodopa intravenously, in addition to their usual oral 
medications. Not one patient experienced hallucinations, although patients had 
clear motor effects and adequate plasma levodopa levels. The authors conclude that 
"visual hallucinations do not relate simply to high levels of [levodopa] or to sudden 
changes in plasma levels." 
 30.  Graham JM, Grünewald RA, Sagar HJ. Hallucinosis in idiopathic 
Parkinson's disease. J Neurol Neurosurg Psychiatry 1997; 63:434-440. 
* This phenomenological study of psychosis in PD confirms earlier evidence that 
psychosis is less common with levodopa than with dopamine agonists. 
 31.  Goetz CG, Vogel C, Tanner CM, Stebbins GT. Early dopaminergic drug-
induced hallucinations in parkinsonian patients. Neurology 1998; 51:811-814. 
* Parkinsonian patients who develop hallucinations early in the course of illness 
show clear clinical differences when contrasted to patients who develop 
hallucinations only after years of illness and treatment. 
 32.  Inzelberg R, Kipervasser S, Korczyn AD. Auditory hallucinations in 
Parkinson's disease. J Neurol Neurosurg Psychiatry 1998; 64:533-535. 
 33.  Snowden JS, Craufurd D, Griffiths HL, Neary D. Awareness of 
involuntary movements in Huntington disease. Arch Neurol 1998; 55:801-805. 
* HD patients underestimated the severity of their movement disorder, but 
accurately reported the consequences, such as falling or knocking over a glass of 
water. If patients had psychologically motivated denial they would deny both. 
Unawareness of chorea did not correlate with dementia. Although other 
interpretations are possible, the authors conclude reasonably that patients have a 
form of anosognosia. The study bears replication in other forms of chorea and in 
tardive dyskinesia. 
This is a non-final version of an article published in final form in: Black KJ, Mink JW. 




 34.  de Boo GM, Tibben A, Lanser JBK, Jennekens-Schinkel A, Hermans J, 
Maat-Kievit A, et al. Early cognitive and motor symptoms in identified carriers of 
the gene for Huntington disease. Arch Neurol 1997; 54:1353-1357. 
* Asymptomatic carriers with normal neurological examination results showed no 
significant differences and performed only minimally worse on any of several 
cognitive tests compared to non-gene-carrying relatives of HD patients. However, 
asymptomatic individuals with abnormal neurologic exams did somewhat worse on 
verbal memory and response inhibition tasks, and clearly worse on several motor 
tasks, than genotypically normal at-risk individuals. The study had low power due 
to group size. 
 35.  Hahn-Barma V, Deweer B, Dürr A, Dodé C, Feingold J, Pillon B, et al. 
Are cognitive changes the first symptoms of Huntington's disease? a study of gene 
carriers. J Neurol Neurosurg Psychiatry 1998; 64:172-177.** In this fairly large 
study from the Salpêtrière, there were statistically significant differences in 
neuropsychological test results between neurologically normal at-risk individuals 
who later were found to have abnormal versus normal number of CAG repeats in 
the huntingtin gene. Logical and verbal memory was most affected. Additionally, 
there were significant correlations of several tests with repeat number within the 
gene carrier group, including response inhibition, memory (Wechsler paired 
associates), and digit symbol tests. 
 36.  Wenzel T, Schnider P, Wimmer A, Steinhoff N, Moraru E, Auff E. 
Psychiatric comorbidity in patients with spasmodic torticollis. J Psychosom Res 
1997; 44:687-690. 
* In this interview study of 44 adult patients with cervical dystonia, panic disorder, 
major depression, and OCD were especially common, although no comparison 
group was examined simultaneously. Most patients with major depression said it 
antedated the torticollis, suggesting that it was not simply a response to pain, 
disability or embarrassment. 
 37.  Fahn S. Psychogenic movement disorders. In: Movement disorders 3. 
Edited by Marsden CD, Fahn S Boston: Butterworth-Heinemann; 1994. pp. 359-
372. 
 38.  Singer HS. Neurobiological issues in Tourette syndrome. Brain & 
Development 1994; 16:353-364. 
 39.  Peterson B, Skudlarski P, Anderson A, Zhang H, Gatenby J, Lacadie C, et 
al. A functional magnetic resonance imaging study of tic suppression in Tourette 
syndrome. Arch Gen Psychiatry 1998; 54:326-333. 
This is a non-final version of an article published in final form in: Black KJ, Mink JW. 




 40.  Kumar R, Lang AE. Coexistence of tics and parkinsonism: Evidence for 
non-dopaminergic mechanims in tic pathogensis. Neurology 1997; 49:1699-1701. 
* This is a report of 4 individuals with tics since childhood, who met historical 
criteria for Tourette Syndrome who developed Parkinson's disease in adulthood. 
There was no change in the tics associated with the onset of parkinsonian symptoms 
(follow-up 3 mos. to 11 yrs.). Further, in the three patients who were treated with l-
dopa (the 4th refused treatment), there was no change in tics associated with l-dopa 
therapy. This report suggests that tics are not due exclusively to dopaminergic 
mechanisms. 
 41.  Swedo SE. Sydenham's chorea: a model of childhood autoimmune 
neurospsychiatric disorders. J Am Med Assoc 1994; 272:1788-1791. 
 42.  Black KJ, Perlmutter JS. Septuagenarian Sydenham's with secondary 
hypomania. Neuropsychiatry Neuropsychol Behav Neurol 1997; 10:147-150. 
 43.  Kurlan R. Tourette's syndrome and 'PANDAS'.  Will the relation bear out? 
Neurology 1998; 50:1530-1534. 
** The author reviews the concept that a spectrum of childhood neurobehavioral 
disorders can follow infection with group A beta-hemolytic streptococcus and 
discusses the possible relationship between tic disorders and antecedant strep 
infections.  This is one of the most thorough rigorous reviews on the subject to date. 
 44.  Riedel M, Straube A, Schwarz M, Wilske B, Muller N. Lyme disease 
presenting as Tourette's syndrome. Lancet 1998; 351:418-419. 
 45.  Swedo SE, Leonard HL, Garvey M, Mittleman B, Allen AJ, Perlmutter S, 
et al. Pediatric autoimmune neuropsychiatric disorders associated with streptococcal 
infections: clinical description of the first 50 cases. Am J Psychiatry 1998; 155:264-
271. 
* The authors review their first 50 cases of tics or OCD associated with GABHS 
infection ("PANDAS"), and make a case for the validity of the diagnostic criteria 
they developed. 
 46.  Singer HS, Giuliano JD, Hansen BH, Hallett JJ, Laurino JP, Benson M, et 
al. Antibodies against human putamen in children with Tourette syndrome. 
Neurology 1998; 50: 1618-1624. 
** This is a study of serum antineuronal antibodies in 41 children with Tourette 
syndrome and 39 age-matched controls. The authors report increased antibodies 
against putamen.  Among subjects with elevated antistreptolysin O or 
This is a non-final version of an article published in final form in: Black KJ, Mink JW. 




antideoxyribonuclease B titers, a significantly larger group of TS subjects had 
elevated antineuronal antibodies. Although the TS subjects had increased 
antineuronal antibodies as a group, several control subjects had increased 
antibodies and several TS subjects did not have increased antibodies as measured 
by ELISA optical density. 
 47.  Gibofsky A, Khanna A, Suh E, Zabriskie J. The genetics of rheumatic 
fever: relationship to streptococcal infection and autoimmune disease. Journal of 
Rheumatology 1991; 18 (suppl 30):1-5. 
 48.  Murphy TK, Goodman WK, Fudge MW, Williams RCJr, Ayoub EM, Dalal 
M, et al. B lymphocyte antigen D8/17: a peripheral marker for childhood-onset 
obsessive-compulsive disorder and Tourette's syndrome? Am J Psychiatry 1997; 
154:402-407. 
 49.  Swedo SE, Leonard HL, Mittleman BB, Allen AJ, Rapoport JL, Dow SP, 
et al. Identification of children with pediatric autoimmune neuropsychiatric 
disorders associated with streptococcal infections by a marker associated with 
rheumatic fever. Am J Psychiatry 1997; 154:110-112. 
 50.  Barr CL, Sandor P. Current status of genetic studies of Gilles de la 
Tourette Syndrome. Can J Psychiatry 1998; 43:351-357. 
* A review of the the progress and obstacles in the search for specific genes 
involved in Tourette Syndrome 
 51.  Thompson M, Comings D, Feder L, George S, O'Dowd B. Mutation 
screening of the dopamine D1 receptor gene in Tourette's syndrome and alcohol 
dependent patients. American Journal of Medical Genetics (Neuropsychiatric 
genetics) 1998; 81:241-244. 
 52.  Hebebrand J, Klug B, Fimmers R, Seuchter SA, Wettke-Schäfer R, Deget 
F, et al. Rates for tic disorders and obsessive compulsive symptomatology in 
families of children and adolescents with Gilles de la Tourette syndrome. J Psychiat 
Res 1997; 31:519-530. 
** This family study of Tourette syndrome (TS) was carefully executed; diagnosis in 
75% of 267 first degree relatives came from examination of patient and/or parental 
interview. There were several clinically relevant findings, but the results are most 
important for their implications for the nosology of obsessive-compulsive symptoms 
in TS patients. 
This is a non-final version of an article published in final form in: Black KJ, Mink JW. 




 53.  Coffey BJ, Miguel EC, Biederman J, Baer L, Rauch SL, O'Sullivan RL, et 
al. Tourette's disorder with and without obsessive-compulsive disorder in adults: are 
they different? J Nerv Ment Dis 1998; 186:201-206. 
** Patients in 3 groups (TS alone, OCD alone, or both) differed significantly in 
rates of several comorbid psychiatric illnesses. Primarily this was due to higher 
rates of comorbidity in the TS+OCD group compared to the OCD group, but the 
TS+OCD group also had higher rates than the TS-only group, except for ADHD. 
After Bonferroni correction for multiple comparisons, the group difference in 
prevalence of body dysmorphic disorder remained statistically significant. 
 54.  Berthier ML, Kulisevsky J, Campos VM. Bipolar disorder in adult patients 
with Tourette's syndrome: a clinical study. Biol Psychiatry 1998; 43:364-370. 
 55.  Molho ES, Feustel PJ, Factor SA. Clinical comparison of tardive and 
idiopathic cervical dystonia. Mov Disord 1998; 13:486-489. 
** Patients with cervical dystonia were retrospectively divided into tardive and 
idiopathic groups on clinical grounds. The tardive patients had more extracervical 
involvement, retrocollis, and dystonic head movements; head tremor and dystonia 
in relatives were found exclusively in the idiopathic group, and torticollis, 
laterocollis, hypertrophy of neck muscles, and sensory tricks were more common in 
the idiopathic group. 
 56.  Kiriakis V, Bhatia KP, Quinn NP, Marsden CD. The natural history of 
tardive dystonia: a long-term follow-up study of 107 cases. Brain 1998; 121:2053-
2056. 
* A retrospective review which underscores the serious and chronic nature of this 
illness. The dystonia was more likely to improve in patients in whom stopping 
neuroleptics was possible. 
 57.  Woerner MG, Alvir JM, Saltz BL, Lieberman JA, Kane JM. Prospective 
study of tardive dyskinesia in the elderly: rates and risk factors. Am J Psychiatry 
1998; 155:1521-1528. 
** A final report from a large, prospective study of tardive dyskinesia (TD) in older 
patients. The risk of TD after 3 years of neuroleptic treatment was over 50%. 
 58.  Barak Y, Swartz M, Shamir E, Stein D, Weizman A. Vitamin E (alpha-
tocopherol) in the treatment of tardive dyskinesia: a statistical meta-analysis. Ann 
Clin Psychiatry 1998; 10:101-105. 
 59.  Chaplin R, Kent A. Informing patients about tardive dyskinesia. 
This is a non-final version of an article published in final form in: Black KJ, Mink JW. 




Controlled trial of patient education. Br J Psychiatry 1998; 172:78-81. 
 60.  Warren JD, Firgaira F, Thompson EM, Kneebone CS, Blumbergs PC, 
Thompson PD. The causes of sporadic and 'senile' chorea. Aust N Z J Med 1998; 
28:429-431. 
 61.  Cassady SL, Adami H, Moran M, Kunkel R, Thaker GK. Spontaneous 
dyskinesia in subjects with schizophrenia spectrum personality. Am J Psychiatry 
1998; 155:70-75. 
 62.  Rogers D. The motor disorders of severe psychiatric illness: a conflict of 
paradigms. Br J Psychiatry 1985; 147:221-232. 
 63.  Stober G, Franzek E, Haubitz I, Pfuhlmann B, Beckmann H. Gender 
differences and age of onset in the catatonic subtypes of schizophrenia. 
Psychopathology 1998; 31:307-312. 
 64.  Stober G, Haubitz I, Franzek E, Beckmann H. Parent-of-origin effect and 
evidence for differential transmission in periodic catatonia. Psychiatr Genet 1998; 
8:213-219. 
 65.  Berardi D, Amore M, Keck PE, Jr., Troia M, dell'Atti M. Clinical and 
pharmacologic risk factors for neuroleptic malignant syndrome: a case-control study. 
Biol Psychiatry 1998; 44:748-754. 
* This study identified clinical as well as pharmacologic risk factors for NMS in 
patients treated with neuroleptics: psychomotor agitation, confusion, disorganized 
behavior, and catatonia; parkinsonism, dystonia, and akathisia; and neuroleptic 
dose, recent dose increases, and parenteral administration. 
 66.  Lee JW. Serum iron in catatonia and neuroleptic malignant syndrome. Biol 
Psychiatry 1998; 44:499-507. 
 67.  Rosebush PI, Mazurek MF. Serum iron and neuroleptic malignant 
syndrome. Lancet 1991; 338:149-151. 
